The authors compared the sensitivity of CEACAM1 and L1 markers to MelanA, S100, and HMB45 and describe results similar to other studies reporting an 87–93% sensitivity in primary melanomas and 60–95% in their corresponding metastatic lymph nodes [63]. This evidence concerns the gene PMEL and melanoma.